{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":10,"sponsored":0,"items":[{"id":"n_cdzg5slgi5qk2fcfkrgq","seq":799635,"kind":"article","title":"MSD ‘키트루다 피하주사’ 국내 도입…18개 암종 35개 적응증","title_en":"MSD 'Keytruda subcutaneous injection' introduced in Korea... 35 indications for 18 cancers","url":"https://www.etoday.co.kr/news/view/2630715","summary":"3주 1분, 6주 2분 투여 기존 정맥주사와 교차 투여 가능 정맥주사(IV) 대비 연간 투여 시간 96.7% 감소 한국MSD의 항PD-1 면...","published":"2026-09-30T00:45:00Z","seen":"2026-09-30T01:33:17Z","lang":"ko","country":"KR","source":{"id":"kite-etoday-co-kr-278ce9","name":"etoday.co.kr","domain":"rss.etoday.co.kr"},"via":"kite-etoday-co-kr-278ce9","topics":["일반"],"authors":["한성주","author"],"entities":[{"id":"Q247489","name":"Merck & Co.","type":"org"}],"story":"st_cdzg5slgi5qk2fcfkrgq","category":"health","category_p":0.83,"sentiment":"neutral","tone":0.19,"political":0.15},{"id":"n_3ivxlahgiygq7lb2pjsa","seq":591560,"kind":"article","title":"“인제니아, MSD가 검증한 '혈관 정상화' 기술…2028년 임상 3상 결과 주목”","title_en":"'Ingenya, MSD-verified 'blood vessel normalization' technology... 2028 clinical phase 3 results to be noted'","url":"https://www.hankyung.com/article/202609292047i","published":"2026-09-29T05:19:08Z","seen":"2026-09-29T06:09:57Z","lang":"ko","country":"KR","source":{"id":"kite-hankyung-com-9ecfa1","name":"hankyung.com","domain":"hankyung.com","outlet":{"wikidata":"Q626241","name":"Korea Economic Daily","type":"newspaper","country":"KR","designations":["newspaper","periodical"]}},"via":"kite-hankyung-com-9ecfa1","authors":["author"],"entities":[{"id":"Q247489","name":"Merck & Co.","type":"org"}],"story":"st_3ivxlahgiygq7lb2pjsa","category":"health","category_p":0.54,"category2":"science-technology","sentiment":"positive","tone":0.5,"political":0.02},{"id":"n_fze3374ykqx7epk4qq6q","seq":550728,"kind":"article","title":"MSD, 中 전임상 항암제에 4억달러 선급…KRAS G12D 공략","title_en":"MSD advances $400 million to China for preclinical cancer drug... targets KRAS G12D","url":"https://www.medipana.com/news/articleView.html?idxno=418372","summary":"MSD가 중국 바이오기업의 전임상 항암 후보물질을 확보하며 KRAS 표적치료제 개발에 나섰다. 아직 사람에게서 효능과 안전성이 확인되지 않은 단계지만, 선급금으로만 4억달러를 지급해 KRAS G12D 변이 치료제의 가능성에 투자했다. MSD는 28일 중국 사이브런치테라퓨틱스(SciBrunch Therapeutics)와 경구용 항암 후보물질 \\'SPR2015\\'의 글로벌 독점 라이선스 계약을 체결했다고 밝혔다. MSD는 전 세계에서 이 물질을 개발·제조·판매할 권리를 얻는다. 사이브런치가 받는 선급금은 4억달러다. 향후 여러 적응증에서","published":"2026-09-28T23:35:26Z","seen":"2026-09-29T00:49:28Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q247489","name":"Merck & Co.","type":"org"},{"id":"Q28371012","name":"KRAS G12D","type":"other"}],"story":"st_fze3374ykqx7epk4qq6q","category":"economy-business","category_p":0.67,"sentiment":"neutral","tone":0.08,"political":0.64},{"id":"n_pbtyajpryl35qycxiwmq","seq":546440,"kind":"article","title":"MSD 중 KRAS 억제 항암 후보 도입","title_en":"MSD introduces KRAS inhibitor cancer candidate in South Korea","url":"https://www.bosa.co.kr/news/articleView.html?idxno=3012911","summary":"[의학신문·일간보사=김자연 기자] MSD가 전임상 경구 KRAS 억제 항암제 신약후보의 세계 독점 권리를 중국 사이브런치 쎄러퓨틱스로 부터 도입했다고 발표했다.이에 MSD는 선금 4억달러를 지급하고 마일스톤까지 포함해 총 21억3000만달러까지 지급할 수 있다. 대상은 선택적 분자 접착 KRAS G12D (ON) 억제제 SPR2015로 여러 KRAS G12D-변이 세포 라인에서 우수한 선택성으로 나노몰 수준에서도 항증식 활성을 나타냈다. 이와 관련, KRAS 변이는 인간 암의 약 1/4에서 일어나는 가운데 G12D 변이는 췌관선암종","published":"2026-09-28T23:14:24Z","seen":"2026-09-29T00:06:25Z","lang":"ko","source":{"id":"kite-bosa-co-kr-134b8e","name":"bosa.co.kr","domain":"bosa.co.kr","outlet":{"wikidata":"Q20445876","name":"Q20445876","type":"newspaper","country":"KR","designations":["newspaper"]}},"via":"kite-bosa-co-kr-134b8e","topics":["medicine","해외"],"authors":["김자연 기자"],"entities":[{"id":"Q247489","name":"Merck & Co.","type":"org"}],"story":"st_pbtyajpryl35qycxiwmq","category":"health","category_p":0.49,"sentiment":"neutral","tone":0.13,"political":0.49},{"id":"n_uufdy6yusull5b44o3fq","seq":438761,"kind":"article","title":"Zimbabwe: MSD Warns of Heavy Rains, Lightning and Strong Winds","url":"https://allafrica.com/stories/202609280231.html","published":"2026-09-28T13:36:37Z","seen":"2026-09-28T13:36:37Z","lang":"en","source":{"id":"allafrica.com","name":"allafrica.com","domain":"allafrica.com","outlet":{"wikidata":"Q2837437","name":"AllAfrica.com","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["agriculture","economy","disaster","health"],"authors":["Elia Ntali"],"entities":[{"id":"Q247489","name":"Merck & Co.","type":"org"}],"story":"st_uufdy6yusull5b44o3fq","category":"weather","category_p":0.52,"sentiment":"negative","tone":-0.58,"political":0.08},{"id":"n_j5hta56qctiqjtyv5t5a","seq":409069,"kind":"article","title":"MSD appoints Vidhya Sundaram as Associate VP of Global Technology Centres","url":"https://www.business-standard.com/companies/news/msd-appoints-vidhya-sundaram-as-associate-vp-of-global-technology-centres-126092800568_1.html","published":"2026-09-28T11:11:39Z","seen":"2026-09-28T11:11:39Z","lang":"en","source":{"id":"business-standard.com","name":"business-standard.com","domain":"business-standard.com","outlet":{"wikidata":"Q2307816","name":"Business Standard","type":"newspaper","country":"IN","designations":["newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","health"],"authors":["Business Standard"],"entities":[{"id":"Q247489","name":"Merck & Co.","type":"org"}],"story":"st_j5hta56qctiqjtyv5t5a","category":"economy-business","category_p":0.3,"category2":"science-technology","sentiment":"neutral","tone":0.61,"political":0.23},{"id":"n_tslsazy4xjr2s67snw3a","seq":401458,"kind":"article","title":"Daiichi Sankyo, MSD withdraw cancer drug application","url":"https://www.pharmaceutical-business-review.com/news/daiichi-sankyo-msd-cancer-application","published":"2026-09-28T10:40:44Z","seen":"2026-09-28T10:40:44Z","lang":"en","source":{"id":"pharmaceutical-business-review.com","name":"pharmaceutical-business-review.com","domain":"pharmaceutical-business-review.com"},"via":"gdelt-gkg-english","topics":["economy","health"],"entities":[{"id":"Q669441","name":"Daiichi Sankyo","type":"org"},{"id":"Q247489","name":"Merck & Co.","type":"org"}],"story":"st_tslsazy4xjr2s67snw3a","category":"health","category_p":0.46,"sentiment":"neutral","tone":-0.25,"political":0.39},{"id":"n_jf6x77dtbeb3o3xbkhha","seq":328170,"kind":"article","title":"MSD warns of thunderstorms, strong winds – DailyNews","url":"https://dailynews.co.zw/msd-warns-of-thunderstorms-strong-winds","published":"2026-09-28T02:37:18Z","seen":"2026-09-28T02:37:18Z","lang":"en","country":"ZW","source":{"id":"dailynews.co.zw","name":"dailynews.co.zw","domain":"dailynews.co.zw","outlet":{"wikidata":"Q3012093","name":"Daily News","type":"newspaper","country":"ZW","designations":["daily newspaper"]}},"via":"gdelt-gkg-english","topics":["economy","disaster"],"authors":["Staff Writer"],"entities":[{"id":"Q247489","name":"Merck & Co.","type":"org"}],"story":"st_jf6x77dtbeb3o3xbkhha","category":"weather","category_p":0.62,"sentiment":"negative","tone":-0.61,"political":0.1},{"id":"n_wyhzrew6fpgffqdjanoa","seq":311940,"kind":"article","title":"MSD·산쿄, 소세포폐암 ADC 美 허가신청 철회…3상에 재도전","title_en":"MSD and Sankyo withdraw small cell lung cancer ADC approval application in the US... retrying in phase 3","url":"https://www.medipana.com/news/articleView.html?idxno=418294","summary":"MSD와 다이이찌산쿄가 공동 개발 중인 항체약물접합체(ADC) \\'이피나타맙 데룩스테칸(I-DXd)\\'의 미국 소세포폐암 가속승인 신청을 자진 철회했다. 두 회사는 현재 진행 중인 임상 3상 결과를 토대로 향후 허가신청 가능성을 다시 평가할 계획이다. 28일 양사 발표에 따르면 철회 대상은 백금계 항암화학요법 중 또는 이후 병이 진행한 성인 확장기 소세포폐암 환자를 대상으로 한 미국 생물학적제제 허가신청(BLA)이다. 발표는 미국 현지시간 25일 이뤄졌다. 양사는 미국 식품의약국(FDA)과 논의한 결과, 임상 2상 \\'IDeate-Lun","published":"2026-09-27T22:09:52Z","seen":"2026-09-27T23:21:41Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q247489","name":"Merck & Co.","type":"org"},{"id":"Q570349","name":"Sanxia District","type":"org"}],"story":"st_wyhzrew6fpgffqdjanoa","category":"economy-business","category_p":0.31,"category2":"health","sentiment":"neutral","tone":-0.1,"political":0.28},{"id":"n_2or4floegzf7qbnnnrta","seq":305965,"kind":"article","title":"TUŽAN DAN ZA ANU BEKUTU! Podelila uspomenu sa Mrkom: Bila mi je potrebna ljubav, toplina i pažnja","url":"https://www.pink.rs/domaci/815814/tuzan-dan-za-anu-bekutu-podelila-uspomenu-sa-mrkom-bila-mi-je-potrebna-ljubav-toplina-i-paznja","summary":"Najveća ljubav Ane Bekute bio je političar Milutin Mrkonjić sa kojim je bila do njegove smrti. Ona i danas čuva uspomenu na njihovu ljubav, a sada je na storiju na Instagramu podelila njihove zajedničke uspomene.","published":"2026-09-27T21:26:01Z","seen":"2026-09-27T22:03:49Z","lang":"en","source":{"id":"kite-pink-rs-a3a22f","name":"pink.rs","domain":"pink.rs","outlet":{"wikidata":"Q366630","name":"Pink (Serbia)","type":"broadcaster","country":"RS","designations":["broadcaster","business","independent record label"]}},"via":"kite-pink-rs-a3a22f","topics":["entertainment"],"entities":[{"id":"Q247489","name":"Merck & Co.","type":"person"}],"image":"https://media.pink.rs/images/34725c7c8-7fe6-433a-919d-11dee1ac91cb/0,0,700,393/1200","story":"st_2or4floegzf7qbnnnrta","category":"human-interest","category_p":0.28,"category2":"arts-culture-entertainment","sentiment":"negative","tone":-0.5,"political":0.03}]}